Eli Lilly says Foundayo 17.2 mg linked to lower diabetes and cardiovascular risk
LLY•Eli Lilly said Foundayo 17.2 mg was associated with a 57% reduction in diabetes risk and an 18% reduction in cardiovascular risk versus placebo.
1. Risk reductions reported
Eli Lilly said Foundayo 17.2 mg was associated with a 57% reduction in diabetes risk and an 18% reduction in cardiovascular risk versus placebo. The company also said Foundayo was associated with reduced predicted long-term risk of type 2 diabetes and cardiovascular disease.
